Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 2021

View Archived Issues

Tetracyclines curb neuropathic pain

Fighting Staphylococcus with Staphylococcus

Dosing begins in first-in-human study of oral AMT-126

VYNE advances development of FMX-114 combination topical gel for AD

FDA approves IND for Q-1802

AbbVie initiates first-in-human study of ABBV-637 as monotherapy or in combination

Addition of ublituximab to ibrutinib significantly improves ORR in patients with CLL

FDA clears IND for TTBT-01 for dry eye disease

VP-001 restores the barrier function of RPE monolayer in patient-derived models of RP11

Topline data presented from phase II INTERACT study of luvadaxistat

Positive interim analysis data from ongoing FURI and CARES phase III trials of ibrexafungerp

Mesoblast International patents cell compositions increasing PTEN-alpha expression

New EFdA prodrugs synthesized at GlaxoSmithKline

First-in-human data presented for SCC-244 in NSCLC

Domain Therapeutics discovers NPFF1 antagonists

Promising results from phase III NAVIGATOR study of tezepelumab

New protein kinase inhibitors identified at BCI Pharma

Applied Pharmaceutical Science identifies new RET inhibitors

BiomX begins phase II study of BX-001 for acne

Pandion Therapeutics develops bispecific PD-1, MADCAM1 antibody for type 1 diabetes

Phase I data reported for CC-90010 in patients with solid tumors

FDA approves Azstarys for ADHD

NeuroSense reports phase IIa data with PrimeC in ALS

Arena reports phase IIb data on olorinab for abdominal pain associated with IBS

Tocilizumab does not significantly improve clinical status in severe COVID-19 pneumonia

Cerecor reports final phase II efficacy data on CERC-002 in hospitalized COVID-19 patients

Poziotinib twice daily effective in patients with EGFR/HER2 exon 20-mutant NSCLC

At ESMO TAT meeting, translating translation inhibition

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...